Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × FED × abiraterone × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

OTHER_GOV 1 OTHER 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasm Metastasis 1

Interventions

Imiquimod 2 relugolix 1 nilutamide 1 histrelin 1 enzalutamide 1 bicalutamide 1 apalutamide 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 Triptorelin Pamoate 1 Thioctic Acid 1 Prednisone 1 Picibanil 1 Methylprednisolone 1 Leuprolide 1 Goserelin 1 Flutamide 1 Androgen Antagonists 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡